Engineered immune cells take aim at Hard-to-Treat blood cancer
NCT ID NCT03672318
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times
Summary
This early-phase study tests a new treatment for people with multiple myeloma that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are modified in a lab to recognize and attack myeloma cells carrying a protein called CD138. The main goal is to find the safest dose and understand side effects. The study involves 25 participants and is no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.